Industry News

WuXi PharmaTech (Cayman) Incand Eli Lilly and Company announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.

The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

[adsense:336x280:8701650588]

DS Biopharma, a biopharmaceutical company, announced that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 (15-HEPE) for fatty liver disorders has been granted by the European Patent Office (EPO).

Five years after the introduction of MenAfriVac, an affordable vaccine for meningitis A produced by Indian firm Serum Institute of India, immunization has led to the near elimination of the deadly disease in Africa's 'meningitis belt', says the Clinical Infectious Diseases journal.

Abcam, a supplier of life science research tools, is to acquire AxioMx, an American antibody technology firm, for US$25m. The firm, based in Cambridge, UK has agreed the deal and will pay $20m to AxioMx with further performance payments of up to $5m over five years. The deal is expected to be completed by the end of this month.

Roche announced the launch of the VENTANA HE 600 system, the latest fully automated hematoxylin and eosin (H&E) tissue staining system that enhances patient and technician safety and produces exceptional staining quality.
The VENTANA HE 600 system delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality in tissue staining. This individual slide staining technology mitigates the risk of specimen cross contamination that can occur with other technologies, helping to reduce patient misdiagnosis.

AstraZeneca, along with its global biologics research and development arm, MedImmune, will present positive data today from the Phase II trial of anifrolumab for the treatment of moderate-to-severe systemic lupus erythematosus (SLE or lupus) at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting in San Francisco.

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced that they have entered into a definitive agreement. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. ("Laurel").

The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to ArmaGen Inc's AGT-181, a potential treatment for patients with Hurler syndrome, a disease that is also known as mucopolysaccharidosis type I (MPS I).

Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for GoNitro for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

[adsense:336x280:8701650588]